Schenone, Aaron D <br/><br/>
Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.  [electronic resource] 

 -  Cancer medicine  Jun 2014 
 - 603-12 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.209  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Chemotherapy, Adjuvant<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Epirubicin--administration & dosage<br/>Female<br/>Humans<br/>Ifosfamide--administration & dosage<br/>Male<br/>Middle Aged<br/>Risk Factors<br/>Sarcoma--drug therapy